No surprise here -- per press clippings of Abbott's Q4 2009 results release:
. . . .Sales of [all Abbott] prescription drugs rose 5.2 percent to $4.85 billion. Global Humira® sales rose 23 percent to $1.66 billion, making it by far the company's biggest product. Sales of Niaspan®, a treatment to raise "good" HDL cholesterol, jumped 15 percent to $254 million, helped by a recent study in which the drug it reduced clogging in neck arteries better than Merck & Co.'s Zetia®. . . .
Also mentioned above is Humira® -- Abbott's biggest seller -- remember, it has a partially shared-history with New Merck, too.